{
    "nct_id": "NCT03643861",
    "official_title": "RAD 1802: a Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)",
    "inclusion_criteria": "* Pathologically proven invasive mammary carcinoma, Invasive ductal carcinoma (IDC) or ductal carcinoma in situ (DCIS) of the breast. Medullary, papillary, mucinous (colloid) and tubular histologies are allowed.\n* Age>50.\n* Maximum pathologic tumor size <2.0cm if invasive carcinoma or < 2.5cm if pure DCIS.\n* Estrogen receptor (ER) positive (>10%).\n* Must be eligible for breast conservation therapy and receive a lumpectomy with pathologic margins of at least 2mm.\n* Must be clinically node negative by physical examination. Sentinel node dissection is not required, but if undertaken, the patient must be pathologically node negative.\n* Zubrod Performance Status 0-2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Multifocal or multicentric cancer.\n* Reception of neoadjuvant chemotherapy.\n* Pure invasive lobular histology.\n* Inability to clearly delineate lumpectomy cavity on post lumpectomy planning scan.\n* Measured maximum PTV of >124cc.\n* Lumpectomy cavity within 5mm of body contour.",
    "miscellaneous_criteria": ""
}